0.97
0.97 (0%)
As of Apr 17, 2025
Unity Biotechnology, Inc. [UBX]
Source:
Company Overview
Unity Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt, or reverse diseases of aging. Our initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | (650) 416-1192 |
| Industry | manufacturing |
| CEO | Anirvan Ghosh |
| Website | www.unitybiotechnology.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-31.2 |
| Net Income | $-26 |
| Net Cash | $-12.2 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -50.3% |
| Profit as % of Stockholder Equity | -400.2% |
Management Effectiveness
| Return on Equity | -400.2% |
| Return on Assets | -69% |
| Turnover Ratio | |
| EBITA | $-31.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $37.7 |
| Total Liabilities | $31.2 |
| Operating Cash Flow | $-20.9 |
| Investing Cash Flow | $8.6 |
| Financing Cash Flow | $0.1 |
